|Min SIP Amount||₹500|
|NAV||₹121.06 (23 Oct 2020)|
|Fund Started||07 Jan 2013|
|Fund Size||₹17 Cr|
|Strides Pharma Science Ltd.||Healthcare||Equity||9.6%|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||8.9%|
|Bharti Airtel Ltd.||Communication||Equity||7.9%|
|Sumitomo Chemical India Pvt. Ltd.||Others||Equity||7.5%|
|Stylam Industries Ltd.||FMCG||Equity||6.8%|
|PTC India Financial Services Ltd.||Financial||Equity||6.0%|
|Reliance Industries Ltd.||Energy||Equity||4.8%|
|Neuland Laboratories Ltd.||Healthcare||Equity||4.4%|
Quant Tax Plan Direct Growth is a Equity Mutual Fund Scheme launched by Quant Mutual Fund. This scheme was made available to investors on 07 Jan 2013. Sanjeev Sharma, Shamil Mehra is the Current Fund Manager of Quant Tax Plan Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹17 Cr and the Latest NAV as of 23 Oct 2020 is ₹121.06.
The Quant Tax Plan Direct Growth is rated Moderately High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 500.
The scheme aims to generate capital appreciation by investing predominantly in equity shares with growth potential. The secondary objective is to give dividend and other income.
Upto Rs. 1.5 lac will be tax free under 80C. Lockin of 3 years. Returns will be taxed at 10%.